Evidence map›Paper›PMID 19879462›Full record

Trial reportJournal of cardiac failure2009

Improvement in health-related quality of life after hospitalization predicts event-free survival in patients with advanced heart failure.

Debra K Moser, Laura Yamokoski, Jie Lena Sun, Ginger A Conway, Karen A Hartman, Judith A Graziano, Cynthia Binanay, Lynne W Stevenson, Escape Investigators

Abstract readComparative StudyMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Journal of cardiac failure, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Guideline
  3. Guideline
  4. Oral Chinese herbal medicine for improvement of quality of life in patients with chronic heart failure: a systematic review and meta-analysis.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2014
    Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Vitamin DBMC cardiovascular disorders · 2017
    Trial
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Article
  14. Article
  15. Global epidemiology of heart failure.Nature reviews. Cardiology · 2024
    Review
  16. Article
  17. Article
  18. Real-World Effectiveness of Ivabradine in Chinese Patients with Chronic Heart Failure: Interim Analysis of the POSITIVE Study.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2022
    Observational
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Debra K MoserUniversity of Kentucky, Lexington, KY 40536-0232, USA. dmoser@uky.edu
Laura Yamokoski
Jie Lena Sun
Ginger A Conway
Karen A Hartman
Judith A Graziano
Cynthia Binanay
Lynne W Stevenson
Escape Investigators

Funding

EVALUATION OF HEART FAILURE AND PULMONARY ARTERY CATHETER-N01HV98177-268098177N01HV098177 · HV · DUKE UNIVERSITY · PI CALIFF, ROBERT M · 1999 to 2006
$1.8M
NHLBI NIH HHS N01 HV098177
6 · The paper itself

Abstract

backgroundHealth-related quality of life (HRQOL) is a major clinical outcome for heart failure (HF) patients. We aimed to determine the frequency, durability, and prognostic significance of improved HRQOL after hospitalization for decompensated HF. METHODS AND

resultsWe analyzed HRQOL, measured serially using the Minnesota Living with Heart Failure Questionnaire (MLHFQ), for 425 patients who survived to discharge in a multicenter randomized clinical trial of pulmonary artery catheter versus clinical assessment to guide therapy for patients with advanced HF. All patients enrolled had 1 or more prior HF hospitalizations or chronic high diuretic doses and 1 or more symptom and 1 sign of fluid overload at admission. Improvement, defined as a decrease of more than 5 points in MLHFQ total score, occurred in 68% of patients by 1 month and stabilized. The degree of 1-month improvement differed (P < .0001 group x time interaction) between 6-month survivors and non-survivors. In a Cox regression model, after adjustment for traditional risk factors for HF morbidity and mortality, improvement in HRQOL by 1 month compared to worsening at 1 month or no change predicted time to subsequent event-free survival (P=.013).

conclusionsIn patients hospitalized with severe HF decompensation, HRQOL is seriously impaired but improves substantially within 1 month for most patients and remains improved for 6 months. Patients for whom HRQOL does not improve by 1 month after hospital admission merit specific attention both to improve HRQOL and to address high risk for poor event-free survival.

Indexed as

Health StatusQuality of LifeAdultAgedCohort StudiesDisease-Free SurvivalFemaleFollow-Up StudiesHeart FailureHospitalizationHumansMaleMiddle AgedPredictive Value of TestsRisk FactorsSurvival Rate

Identifiers

PMID19879462
PMCPMC2772831

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.